Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe®獲FDA核可，LeukoStrat® CDx FLT3 Mutation Assay可用於為Rydapt®挑選患者的搭配診斷檢驗，並成為第一種AML搭配診斷工具

聖地牙哥, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc.今日宣佈LeukoStrat® CDx FLT3 Mutation Assay獲得上市前核可；這是一間全球公司，為腫瘤學、personalized molecular diagnostics®和personalized molecular...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe® recibe la aprobación de la FDA para el ensayo de mutación LeukoStrat® CDx FLT3, prueba de diagnóstico complementaria, para la selección de pacientes para Rydapt® y primer diagnóstico complementario en AML

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., una compañía global con más de veinte años de experiencia ofreciendo soluciones de pruebas de clonalidad y...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe® Terima Kelulusan FDA bagi Ujian Diagnostik Pendamping LeukoStrat® CDx FLT3 Mutation Assay untuk Pemilihan Pesakit bagi Rydapt® dan merupakan Diagnostik Pendamping Pertama untuk AML

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., sebuah syarikat global yang memiliki lebih daripada 20 tahun pengalaman dalam menyediakan klonaliti dan...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe® Menerima Persetujuan FDA untuk Uji Diagnostik Pendamping Asai Mutasi FLT3 CDx LeukoStrat® bagi Pasien Terseleksi untuk Rydapt® dan merupakan Diagnostik Pendamping Pertama untuk AML

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., sebuah perusahaan global dengan pengalaman lebih dari 20 tahun yang menyediakan solusi pengklonaan dan uji penanda...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe® recebe aprovação da FDA para o teste de diagnóstico complementar de exame de mutação LeukoStrat® CDx FLT3 para a seleção de pacientes para Rydapt® e é o primeiro diagnóstico complementar para LMA

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- A Invivoscribe® Technologies Inc., uma empresa global com mais de 20 anos de experiência no fornecimento de soluções para teste de clonalidade e...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe® ได้รับการรับรองจาก FDA สำหรับวิธีทดสอบการวินิจฉัยควบคู่ของ LeukoStrat® CDx FLT3 Mutation Assay เพื่อคัดเลือกอาสาสมัครสำหรับ Rydapt® และเป็นวิธีเพื่อการวินิจฉัยควบคู่แรกสำหรับโรค AML

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc. บริษัทระดับโลกที่มีประสบการณ์มากกว่า 20 ปี นำมาซึ่งแนวทางการทดสอบเซลล์และตัวชี้วัดทางชีวภาพสำหรับสาขาเนื้องอกวิทยา...
02 mai 2017 08h43 HE | Source: Invivoscribe, Inc.

Invivoscribe®用于为Rydapt®甄选患者的LeukoStrat® CDx FLT3 Mutation Assay伴随诊断检查获FDA批准，成为第一种AML伴随诊断工具

圣地亚哥, May 02, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc.今日宣布LeukoStrat® CDx FLT3 Mutation Assay获得上市前批准，这是一家全球公司，为肿瘤学、personalized molecular diagnostics®和personalized molecular...
28 avr. 2017 12h46 HE | Source: Invivoscribe, Inc.

Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML

SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields...
28 avr. 2017 11h30 HE | Source: Novartis Pharma AG

Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)

Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement in...
06 mars 2017 10h05 HE | Source: Research and Markets

Global Next Generation Sequencing (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) Markets, 2020

Dublin, March 06, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive...

Page précédente

Page suivante